Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Ko SC[original query] |
---|
Reported reasons for testing among hepatitis B virus infected patients, - Chronic Hepatitis Cohort Study (CHeCS), United States, 2006-2010
Gerbi GB , Rupp LB , Ko SC , Moorman A , Holmberg SD , Xu F . Liver Int 2014 34 (6) e162-3 Although 800,000-2 million persons in the United States have chronic hepatitis B virus (HBV) infection(1), only an estimated two-thirds of them have a diagnosis. We examined the reasons HBV-infected participants in the CheCS had been tested. CheCS is an observational cohort study created to assess the natural history and clinical encounters of chronic viral hepatitis in the United States. Of 3,358 patients aged ≥18 years who met the inclusion criteria for chronic hepatitis B virus (HBV) infection (2), 2,725(81.2%) were sampled randomly for survey. After the exclusion of 450 patients who died or could otherwise not be contacted, the remaining 2,275 (67.7%) patients were surveyed by U.S. mail or telephone. |
Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women
Ko SC , Schillie SF , Walker T , Veselsky SL , Nelson N , Lazaroff J , Crowley S , Dusek C , Loggins K , Onye K , Fenlon N , Murphy TV . Vaccine 2014 32 (18) 2127-33 PURPOSE: Annually, an estimated 25,000 infants are born to hepatitis B surface antigen (HBsAg)-positive women in the United States. Hepatitis B (HepB) vaccine and hepatitis B immune globulin (HBIG) are recommended at birth, followed by completion of vaccine series and post-vaccination serologic testing (PVST). In a large cohort of infants born to HBsAg-positive women, factors influencing vaccine response were evaluated. METHODS: Data were from HBsAg-negative infants born to HBsAg-positive women in the Enhanced Perinatal Hepatitis B Prevention Program (EPHBPP) from 2008 to 2013. Vaccine non-responders were defined as infants with antibody to hepatitis B surface antigen (anti-HBs) <10mIU/mL at PVST after receiving ≥3 vaccine doses. Multivariable analyses modeled statistically significant predictor variables associated with non-response. RESULTS: A number of 17,951 maternal-infant pairs were enrolled; 8654 HBsAg-negative infants born to HBsAg-positive mothers received ≥3 doses of vaccine with anti-HBs results. 8199 (94.7%) infants responded to a primary HepB series; 199 (94.8%) to a second series. Factors associated with anti-HBs <10mIU/mL included gestational age <37 weeks, vaccine birth dose >12h after birth, timing of final vaccine dose <6 months after birth, receipt of 3 vs. 4 vaccine doses, and PVST interval >6 months from final vaccine dose in bivariate analysis. PVST interval >6 months from final vaccine dose (OR=2.7, CI=2.0, 3.6) was significantly associated with anti-HBs <10mIU/mL; the proportion increased from 2% at 1-2 months to 21.6% at 15-16 months after the final dose. Receipt of a 4th dose improved the response rate (OR=0.5, CI=0.3, 0.8). CONCLUSIONS: Ninety-five percent of a large cohort of uninfected infants born to HBsAg-positive mothers in the United States responded to primary HepB vaccine series. The proportion of infants with anti-HBs <10mIU/mL increased with longer interval between the final vaccine dose and PVST. Optimal timing of PVST is within 1-2 months of final vaccine dose to avoid unnecessary revaccination. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure